Avita Medical (RCEL) to Release Quarterly Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.36) per share and revenue of $26.27 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Avita Medical Stock Performance

Shares of Avita Medical stock opened at $4.00 on Wednesday. The business’s 50 day moving average price is $3.70 and its 200 day moving average price is $4.32. The company has a market cap of $121.96 million, a price-to-earnings ratio of -2.21 and a beta of 1.78. Avita Medical has a one year low of $3.22 and a one year high of $11.25.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on RCEL. BTIG Research upgraded Avita Medical from a “sell” rating to a “neutral” rating in a report on Thursday, November 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avita Medical in a report on Monday, December 29th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Avita Medical in a report on Monday, January 26th. Zacks Research raised shares of Avita Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, December 19th. Finally, Lake Street Capital increased their price objective on Avita Medical from $3.00 to $3.50 and gave the stock a “hold” rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Avita Medical presently has a consensus rating of “Hold” and an average price target of $5.50.

Institutional Trading of Avita Medical

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new stake in Avita Medical in the first quarter valued at approximately $799,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Avita Medical in the 1st quarter valued at $374,000. Jane Street Group LLC raised its holdings in shares of Avita Medical by 20.4% in the 1st quarter. Jane Street Group LLC now owns 63,744 shares of the company’s stock valued at $519,000 after buying an additional 10,789 shares during the period. Strs Ohio acquired a new position in Avita Medical during the 1st quarter worth about $116,000. Finally, Rhumbline Advisers boosted its holdings in Avita Medical by 8.8% during the 2nd quarter. Rhumbline Advisers now owns 42,168 shares of the company’s stock valued at $223,000 after acquiring an additional 3,393 shares during the period. Institutional investors and hedge funds own 27.66% of the company’s stock.

Avita Medical Company Profile

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.